Public reporting burden for this coliection of infomiation Is estimated to average 1 hour per response, including the time for reviewing instmctions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of infomiation. 
Discovery of novel mammary developmental and cancer genes using ENU mutagenesis
This project seeks to discover new genes involved in mammary glan^ carcinogenesis, by screening for reduced latency to palpable mammary tumors in response to the myc oncogene, that is produced by the loss of a second gene knocked out by random ENU mutagenesis. This project^dravi's upon the large scale recessive ENU mutagenesis project at the John Curtin School Australian National University. ^ We have successfully imported, rederived and cleared from Quarantine the bi-transgeneic inducible myc model of mammary carcinogenesis devised by Prof Lewis Chodosh. We have established and expanded the colony and we have begun production of animals to be mated with ENU mutagenised animals. We are currently approximately 2 months behind our statement of work, due mainly to a delay experienced in the importation process. On the positive side the construction of a very large new mouse facility at the Australian National University is ahead of time and is due for commissioning in April next year, which should decrease the time required for pedigree screening and expansion in 2004 
Introduction
To date there has been no systematic search for genes controlling mammary development and carcinogenesis, and this project seeks to undertake the first such search by participation in the large scale recessive ENU mutagenesis project currently being conducted by Prof. Chris Goodnow, at the John Curtin School, Australian National University (ANU).
Body
In the first annual report we proposed a modified Statement of Work that included the use of the tet/c- Mate Gl males to homozygous Tet-myc bitransgenic females to produce G2 offspring. c.
Mate G2 females with their fathers to produce 25 G3 females per ENU or control pedigree. d.
Induce transgene expression at 9 weeks of age with doxycycline. Monitor G3 females for mammary tumors by palpitation every 10 days. Select females with tumors from the ENU group which become palpable before tumors are seen in the control group. e.
Continue intercross/backcross if no informative recombinations are found. f.
Identify candidate genes at a sub 1 cM locus from the mouse genome map. Exclude those not expressed in the mammary gland. Begin sequencing of remaining candidates to identify ENU-induced mutation.
Progress in relation to the SOW.
In the first 12 months of the amended SOW we imported the two transgenie lines from the Laboratory of A/Prof Lewis Chodosh, and had them released from quarantine. The lines have been rederived and placed behind the barrier of our SPF facility at the Garvan Institute. The colonies of each line were established and PCR based genotyping assays were established and verified. We commenced the three stage intercross of these lines to provide animals (TOM*/* MTB */ in the scheme below) suitable for breeding with ENU mutagenised animals. We estimated that we were 2 months behind our anticipated position in the SOW and anticipated transferring these animals to the new ANU facility to begin the breeding with the ENU mutagenised mice.
In the 12 months to Sept 2004 we continued to breed TOM/MTB mice ready for transfer to the ANU facility. The facility was completed on schedule mid year and is now operational, see httpf/Zwww.apf.edu.au/about/ for details and a downloadable .pdf outlining the new facility. The facility is now reftising to accept our animals without rederivation into thek facility, despite the demonstrated SPF status of our animals, to comply with the instructions of their newly appointed Scientific Advisory Committee. This decision of the Scientific Advisory Committee was made despite the objections of the Facility Management and was not foreseen or expected and thus not included in the SOW. As a result our project has now been delayed while rederivation procedures are put in place. The TOM/MTB mice are now scheduled to be transferred to the ANU facility in the week6-10 December 2004. This unforeseen problem has resulted in a 12 month delay in this project.
Despite these setbacks we intend to continue this work as it has the potential to discover both new mammary tumour suppressor genes and genes essential for myc action. These genes will be excellent new therapeutic targets for breast canecr. The intended experimental work is reproduced below from last year's annual report and will commence in January 2005. Production of animals suitable for breeding to END mutagenised males.
The tet inducible system is bitransgenic, requiring the intercross of the imported mice to produce animals suitable for breeding, as follows.
1 .TOM*/* bred with MTB */ produces 50% TOM*/, MTB*/ 2. TOM*/, MTB*/ bred with TOM*/* produces 25% TOM*/*, MTB*/ 3. TOM*/*, MTB*/ bred with TOM*/* produces 50% TOM*/*, MTB*/ suitable for breeding with ENU mice.
Cross with ENU mice.
We will make two populations, a control population without ENU mutations to accurately establish the kinetics of tumour induction, and a test population to screen for ENU mutations which accelerate or prevent tumourigenesis in response to myc. We will test each for dominantly and recessively acting mutations
Control population
wt C57B16 male mated with FVB TOM*/* MTB */ female. Wt population-aim for 320 animals made from 20
pedigrees. These animals are generated first and establish the normal profile of tumoxir onset in response to induction of myc.
Test population
Gl: Gl males produced by breeding ENU treated B6 males with normal B6 females. Gl B16 male mated with FVB TOM*/* MTB */ female (test group, begin 12 weeks after WT group begins). 16 animals per pedigree, 200 pedigrees.
Dominant screen
Breed and keep eight female G2 progeny that are TOM */ MTB */ =50% of females (requires average of 16 females to be bred and typed from each pedigree ■ n So 4/16 of animals are the exact genotype but 9/16 have both TOM and MTB transgenes, but the MTB*/* animals (3/16) will be poor breeders. How tumorigenesis will be effected by dosage of TOM and MTB is unknown. The system shows titratable expression with Dox, so with luck gene dosage will not dramatically effect tumour onset. It may be possible to distinguish homo2ygotes from hemizygotes using quantitative PCR.
We will need to test this as we go in the control group. We expect that a combination of F2 FVB/B16 and variable gene dosage will make tumor onset more variable, but dramatic phenotypes, such as no tumors, should remain detectable. Screen and map as for the dominant screen.
Key research acdomplishments
• Completion of the intercross of the the two lines for production of TOM*/* MTB */ animals for breeding to ENU mutagenised males.
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